Market Closed -
Other stock markets
|
Pre-market 07:00:26 am | |||
13.01 USD | 0.00% | 12.92 | -0.65% |
Financials (USD)
Sales 2024 * | 15.86B | Sales 2025 * | 16.35B | Capitalization | 14.74B |
---|---|---|---|---|---|
Net income 2024 * | 1.54B | Net income 2025 * | 1.44B | EV / Sales 2024 * | 1.85 x |
Net Debt 2024 * | 14.62B | Net Debt 2025 * | 12.12B | EV / Sales 2025 * | 1.64 x |
P/E ratio 2024 * |
10.4
x | P/E ratio 2025 * |
9.73
x | Employees | 35,737 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.71% |
Latest transcript on Teva Pharmaceutical Industries Limited
1 week | -1.29% | ||
Current month | -7.80% | ||
1 month | -6.34% | ||
3 months | +8.69% | ||
6 months | +58.85% | ||
Current year | +24.62% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 55 | 22-12-31 |
Eli Kalif
DFI | Director of Finance/CFO | 51 | 19-12-21 |
Eric Hughes
CTO | Chief Tech/Sci/R&D Officer | - | 22-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gerald Lieberman
BRD | Director/Board Member | 77 | 15-08-31 |
Janet Vergis
BRD | Director/Board Member | 60 | 20-06-08 |
Sol Barer
CHM | Chairman | 76 | 14-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
6.38% | 13 M€ | -.--% | ||
0.27% | 18 M€ | +3.04% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 13.01 | 0.00% | 7,499,725 |
24-04-23 | 13.01 | +1.01% | 8,982,074 |
24-04-22 | 12.88 | +0.16% | 7,945,162 |
24-04-19 | 12.86 | +0.63% | 10,124,993 |
24-04-18 | 12.78 | -3.03% | 8,957,330 |
Delayed Quote Nyse, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.62% | 14.74B | |
+25.61% | 660B | |
+23.66% | 562B | |
-5.24% | 358B | |
+16.49% | 322B | |
+8.28% | 297B | |
+13.15% | 219B | |
-9.65% | 196B | |
+6.86% | 199B | |
-8.75% | 149B |
- Stock Market
- Equities
- TEVA Stock